Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Preventing foodborne illness from consuming decomposing food Reducing food waste by preserving unused or uneaten food for later use Storage of harvested and processed plant and animal food products for distribution to consumers Enabling a better balanced diet throughout the year Preserving pantry food, such as spices or dry ingredients like rice and flour, for eventual use in cooking Preparedness for catastrophes, emergencies and periods of food scarcity or famine, whether as basic emergency preparedness (for most people) or in its more extreme form of survivalism (prepping) Religious reasons: for example, leaders in the LDS Church (Church of Jesus Christ of Latter-day Saints) instruct church members to store food. Protection from animals or theft
Since the 2000s, cursive writing has been de-emphasized in public education. As a result, Generation Z are less likely to read and write in cursive. Some states introduced legislation to teach it in their jurisdiction, partly because some 80% of historical records and documents of the United States was written by hand in cursive. The percentage of American fourth-graders proficient in reading declined during the late 2010s, according to the National Assessment of Educational Progress (NAEP). There have been numerous reports in the 2010s on how U.S. students were falling behind their international counterparts in the STEM subjects, especially those from (East) Asia. For example, American schoolchildren put up a mediocre performance on the Program for International Student Assessment (PISA), administered to fifteen-year-old students around the world on reading comprehension, mathematics, and science, falling in the middle of the pack in 2015. In fact, reading scores dropped for all ethnic groups except Asians in the late 2010s, according to the NAEP. Nevertheless, American students ranked above the OECD average in science and computer literacy, as of 2021. As of 2024, NAEP data showed that the reading and mathematical skills of American schoolchildren on average still had not recovered from the COVID-19 pandemic. Furthermore, while the strongest students had regained lost grounds, the weakest continued to fall behind. An emphasis on rote memorization and speed gives as many as one in three students age five and up mathematical anxiety.
Biophytum sensitivum, also known as little tree plant, or Mukkutti (in Malayalam) is a species of plant in the genus Biophytum of the family Oxalidaceae. It is commonly found in Kerala, wet lands of Nepal, tropical India and in other Southeast Asian countries and is used for medicinal purposes in Nepal and India. The plant is also a common weed in disturbed environments, but in captivity, Biophytum sensitivum is particularly sensitive to spider mites. Investigations have been undertaken into the plant's chemistry, biological activities, and medicinal uses. Similarly to Mimosa pudica, the leaflets of Biophytum sensitivum are able to move rapidly in response to mechanical stimulation such as touch.
=== Even- vs odd-chained fatty acids === Most naturally occurring fatty acids are even-chained, e.g. stearic (C18:0) and oleic (C18:1), meaning they are composed of an even number of carbon atoms; odd-chained fatty acids (OCFA) also occur, albeit far less frequently. The most common OCFA are the saturated C15 and C17 derivatives, pentadecanoic acid and heptadecanoic acid respectively, which are found in dairy products. On a molecular level, OCFAs are biosynthesized and metabolized slightly differently from the even-chained relatives.
Sources: en.wikipedia.org
=== Other biosynthetic pathways === Carbamoyl phosphate is a carbamate mixed anhydride that is an intermediate in the urea cycle and the biosynthesis of pyrimidines. 5-carboxyamino-1-(5-phospho-D-ribosyl)imidazole (N5-CAIR), a carbamate derivative of aminoimidazole, is an intermediate in the biosynthesis of inosine. Both carbamates are produced via reaction of −NH2 groups with carboxyphosphate (HO−C(O)−OPO2−3).
The Enzyme Function Initiative (EFI) is a large-scale collaborative project aiming to develop and disseminate a robust strategy to determine enzyme function through an integrated sequence–structure-based approach. The project was funded in May 2010 by the National Institute of General Medical Sciences as a Glue Grant which supports the research of complex biological problems that cannot be solved by a single research group. The EFI was largely spurred by the need to develop methods to identify the functions of the enormous number proteins discovered through genomic sequencing projects.
For dinosterol derivatives, analysis is typically carried out by capillary gas chromatography and capillary gas chromatography-mass spectrometry. The mass spectrum of dinosterol as the TMS-ether shows characteristic ions at m/z 500 (M+), 429, 388, 359, 339 and 271. The base peak at m/z 69 is diagnostic for the A:2-unsaturated 23,24-dimethyl sidechain. Other purification techniques for dinosterol include various combinations of thin layer (TLC) and column chromatography with a variety of phases, AgNO3 impregnated Silica gel chromatography, normal phase-high performance liquid chromatography (NP-HPLC), and reversed phase-high performance liquid chromatography (RP-HPL).An alternative method has been proposed for purifying dinosterol from complex mixtures of sedimentary lipids for the purpose of hydrogen isotope analysis via gas chromatography-isotope ratio mass spectrometry (GC-IRMS). Reversed phase-high performance liquid chromatography (RP-HPLC) is used to separate dinosterol from structurally similar 4α-methyl sterols that co-elute on GC analysis, which allows for baseline resolution of dinosterol. For samples that contain a variety of 4a-methyl sterols, RP-HPLC purification can be preceded by NP-HPLC purification.
Sources: en.wikipedia.org
=== Non-TNFi biologics === Non-TNFi "biologic" drugs used in the treatment of ankylosing spondylitis include drugs that target different pathways involved in the inflammatory process. Two of the most important drugs in this class target IL-17, an important part of the inflammatory system: secukinumab and ixekizumab. They are often considered in cases where TNFi drugs are not effective or cause too many side effects. Additionally, they may sometimes be used as an adjunct to a TNFi when symptoms persist, but improve, while the patient is on the TNFi. The choice of a specific non-TNFi biologic depends on various factors, including the patient's medical history, preferences, and the recommendations of the healthcare provider. Ustekinumab has frequently been used as a second-line therapy for AS, but it has recently been scrutinized for a lack of efficacy, and is no longer recommended.
Singer noted in 1949 that Psilocybe cubensis had psychoactive properties. In Australia, the use of psychoactive mushrooms grew rapidly between 1969 and 1975. In a 1992 paper, locals and tourists in Thailand were reported to consume P. cubensis and related species in mushroom omelets—particularly in Ko Samui and Ko Pha-ngan. At times, omelets were adulterated with LSD, resulting in prolonged intoxication. A thriving subculture had developed in the region. Other localities, such as Hat Yai, Ko Samet, and Chiang Mai, also had some reported usage. In 1996, jars of honey containing Psilocybe cubensis were confiscated at the Dutch-German border. Upon examination, it was revealed that jars of honey containing psychedelic mushrooms were being sold at Dutch coffee shops. P. cubensis is one of the most widely known of the psilocybin-containing mushrooms used for triggering psychedelic experiences after ingestion. Its major alkaloids are:
Diagnosis is a 2019 documentary television series. The series follows Dr. Lisa Sanders as she attempts to help patients with rare illnesses and searches for a diagnosis and cure using wisdom of the crowd methods. The show is based on her column for The New York Times Magazine. It was released on August 16, 2019, on Netflix.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.